Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14
NCT ID: NCT00015340
Last Updated: 2017-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
582 participants
INTERVENTIONAL
1999-08-31
2001-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5
NCT00000330
Buprenorphine and Naloxone for the Treatment of Opiate Dependence - 1
NCT00015171
Buprenorphine/Naloxone for Opiate-Dependence Treatment - 1
NCT00015028
Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid Dependence
NCT00134914
Buprenorphine/Naloxone for Treatment of Opiate Dependence - 9
NCT00000344
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Buprenorphine/Naloxone
Buprenorphine/naloxone
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Buprenorphine/naloxone
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
59 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
New York MDRU
OTHER
National Institute on Drug Abuse (NIDA)
NIH
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paul Casadonte, M.D.
Role: STUDY_CHAIR
New York VAMC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California
Los Angeles, California, United States
VA Medical Center
Tampa, Florida, United States
VA Medical Center
Hines, Illinois, United States
New York VAMC
New York, New York, United States
VA PUget Sound Helath Care System
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Y01-5-0013-14
Identifier Type: -
Identifier Source: secondary_id
NIDA-5-0013-14
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.